The Delaware Supreme Court affirmed Friday a trial court’s decision in favor of Teva Pharmaceutical Industries Ltd.'s US unit ...

UBS analyst Ashwani Verma increased the price target for Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to $30 from the previous $28 while keeping a Buy rating on the shares. Verma highlighted Teva as ...

Teva Pharmaceutical Industries Ltd is a global leader in the pharmaceutical industry, specializing in the development, manufacture, and distribution of generic and specialty medicines, as well as ...

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on TEVA stock, giving a Buy rating on January 21.Invest ...

UBS raised the firm’s price target on Teva (TEVA) to $30 from $28 and keeps a Buy rating on the shares. Teva, one of the firm’s top picks for ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

Diversify Advisory Services LLC raised its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 2.5% during the fourth quarter, according to its most recent ...

Teva Pharmaceutical Industries sues CMS over Medicare drug pricing negotiations policy, claiming agency has unchecked ...

After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $20.44 which represents a decrease of $-0.50 or -2.39% from the prior close of $20.94. The stock opened at $20.95 and ...

Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Seana Smith and Madison Mills on Catalysts to discuss what both the pharmaceutical company and industry at large are expecting from Trump's ...

Technical analysis for Teva Pharmaceutical Industries Limited American Depositary Shares TEVA including support levels resistance levels and stop losses for TEVA ...